ReShape Lifesciences Future Growth
Future criteria checks 2/6
ReShape Lifesciences is forecast to grow earnings and revenue by 46.8% and 26.1% per annum respectively while EPS is expected to grow by 68.2% per annum.
Key information
46.8%
Earnings growth rate
68.2%
EPS growth rate
Medical Equipment earnings growth | 16.6% |
Revenue growth rate | 26.1% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | n/a |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2024 | 19 | -19 | N/A | N/A | 1 |
12/31/2023 | 16 | -19 | N/A | N/A | 2 |
12/31/2022 | 11 | -35 | N/A | N/A | 2 |
9/30/2022 | 11 | -65 | -23 | -22 | N/A |
6/30/2022 | 12 | -71 | -25 | -25 | N/A |
3/31/2022 | 13 | -65 | -21 | -21 | N/A |
12/31/2021 | 14 | -62 | -16 | -15 | N/A |
9/30/2021 | 14 | -35 | -14 | -14 | N/A |
6/30/2021 | 14 | -22 | -7 | -7 | N/A |
3/31/2021 | 12 | -22 | -8 | -7 | N/A |
12/31/2020 | 11 | -22 | -9 | -9 | N/A |
9/30/2020 | 12 | -38 | -8 | -8 | N/A |
6/30/2020 | 12 | -62 | -12 | -11 | N/A |
3/31/2020 | 15 | -74 | -12 | -12 | N/A |
12/31/2019 | 15 | -74 | -14 | -14 | N/A |
9/30/2019 | 11 | -52 | -20 | -20 | N/A |
6/30/2019 | 8 | -28 | -20 | -20 | N/A |
3/31/2019 | 4 | -35 | -24 | -24 | N/A |
12/31/2018 | 1 | -38 | -28 | -27 | N/A |
9/30/2018 | 0 | -42 | -29 | -29 | N/A |
6/30/2018 | 1 | -47 | -30 | -30 | N/A |
3/31/2018 | 1 | -30 | -30 | -29 | N/A |
12/31/2017 | 1 | -30 | -25 | -25 | N/A |
9/30/2017 | 1 | -29 | -19 | -19 | N/A |
6/30/2017 | 1 | -25 | -18 | -18 | N/A |
3/31/2017 | 1 | -23 | -18 | -18 | N/A |
12/31/2016 | 1 | -23 | -21 | -21 | N/A |
9/30/2016 | 1 | -26 | -23 | -22 | N/A |
6/30/2016 | 1 | -23 | N/A | -24 | N/A |
3/31/2016 | 0 | -26 | N/A | -24 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 24O is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 24O is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 24O is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 24O's revenue (26.1% per year) is forecast to grow faster than the German market (4.6% per year).
High Growth Revenue: 24O's revenue (26.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 24O's Return on Equity is forecast to be high in 3 years time